natgillin/translations-raw huggingface dataset:
Glucosamine was mainly introduced on the world-wide market as a foodsupplement but with the aim to improve symptoms in patients with osteoarthritis or joint pain or function.
Glukozamin so začeli tržiti po vsem svetu kot prehransko dopolnilo, vendar z namenom lajšanja simptomov pri bolnikih z osteoartritisom ali bolečin v sklepih ali z namenom izboljšanja funkcije sklepov.
During their September 2006 meeting, the CHMP, in the light of the overall data submitted and the scientific discussion within the Committee, was of the opinion that the benefit/risk ratio is favourable for Glucomed and associated names for the relief of symptoms in mild to moderate osteoarthritis of the knee, that there was no objection for the granting of a Marketing Authorisation and that the Summary of Product Characteristics, labelling and package leaflet of the Reference Member State
Na sestanku v septembru 2006 je bil CHMP ob upoštevanju vseh predloženih podatkov in znanstvene razprave v okviru Odbora mnenja, da je razmerje med koristmi in tveganji za zdravilo Glucomed in z njim povezana imena za lajšanje simptomov blagega do zmernega osteoartritisa kolena ugodno, da ni nikakršnih zadržkov za izdajo dovoljenja za promet z zdravilom in da je treba Povzetek glavnih
Glucomed and associated names, 625 mg, tablet, contains glucosamine which is an endogenous substance, a normal constituent of the polysaccharide chains of cartilage matrix and synovial fluid glucosaminoglycans.
Zdravilo Glucomed in z njim povezana imena, 625 mg tablete, vsebujejo glukozamin, ki je endogena snov in je običajen gradnik polisaharidnih verig v hrustančnem matriksu in glikozaminoglikanov v sinovijski tekočini.
Navamedic ASA submitted applications for mutual recognition of Glucomed and associated names, 625 mg, tablet on the basis of the marketing authorisation granted by Sweden on 4 August 2005.
Na podlagi dovoljenja za promet z zdravilom, izdanega na Švedskem 4. avgusta 2005, je družba Navamedic ASA podala vloge za medsebojno priznavanje zdravila Glucomed in z njim povezanih imen, 625 mg tablete.
This summary was last updated in: 04-2013.
Ta povzetek je bil nazadnje posodobljen 04-2013.
Immunity starts after three weeks and lasts for three months.
Imunost se razvije po treh tednih in traja tri mesece.
This can be up to 2 cm in diameter after first injection and up to 5 cm after the second, but they usually disappear within three weeks.
Po prvi injekciji lahko v premeru meri do 2 cm, po drugi injekciji pa do 5 cm, vendar navadno izgine v treh tednih.
The antibodies are also passed on from mother to piglet through the colostrums (first milk) and milk.
Protitelesa se od samice na pujska prenašajo tudi prek kolostruma (prvega mleka) in mleka.
Vaccines work by ‘teaching' the immune system (the body's natural defences) how to defend itself against a diseases.
Cepiva delujejo tako, da imunski sistem (naravno obrambo telesa) naučijo, kako naj se brani pred boleznijo.
Wash and disinfect hands and equipment after use.
Po uporabi si operite in razkužite roke ter opremo.
The vaccine also contains ‘adjuvants' (a compound containing aluminium as well as mineral oil, an emulsifier and a detergent) to stimulate a better response.
Cepivo vsebuje tudi adjuvans (spojino, ki vsebuje aluminij, mineralno olje, emulgator in detergent) za stimulacijo boljšega odziva.
Accidental injection can cause severe pain and swelling, particularly if the vaccine is injected into a joint or finger.
Nenamerno injiciranje lahko povzroči hudo bolečino in oteklino, še zlasti v primeru nenamernega injiciranja v sklep ali prst.
This protects the pigs against the disease.
To pomaga zaščititi prašiče pred boleznijo.
Breeding boars (male pigs) should be revaccinated every six months.
Plemenske merjasce (samce) je treba ponovno cepiti vsakih šest mesecev.
It prevents death and symptoms of the disease and reduces the shedding of the virus.
Cepivo preprečuje pogin in simptome bolezni ter zmanjšuje izločanje virusa.
Female breeding pigs should be revaccinated before their first mating or during each pregnancy, three to six weeks before giving birth.
Plemenske samice je treba ponovno cepiti pred prvim parjenjem ali med vsako brejostjo, tri do šest tednov pred skotitvijo.
The virus has been genetically modified: it has had one of its gene deleted (the gene that makes it able to produce an enzyme called thymidine kinase) and this is what makes it weaker.
Virus je bil gensko spremenjen: odstranjen je bil eden izmed genov (gen, ki omogoča tvorjenje encima timidin kinaza), zato je virus šibkejši.
To vaccinate a whole herd, one dose should be given to every male and female breeding pig every four months.
Za cepljenje cele črede se priporoča dajanje enega odmerka vsakemu plemenskemu samcu in samici vsake štiri mesece.
The studies compared the levels of infection in vaccinated and unvaccinated pigs.
V raziskavah so primerjali stopnjo okužbe pri cepljenih in necepljenih prašičih.
When a pig is given the vaccine, the immune system recognises the weakened viruses as ‘foreign' and makes antibodies against them.
Ko prašič prejme cepivo, imunski sistem prepozna oslabljene viruse kot tujke in proti njim razvije protitelesa.
In case of accidental injection, seek prompt medical advice and show the Package Leaflet to the doctor.
V primeru nenamernega injiciranja nemudoma poiščite medicinsko pomoč in pokažite zdravniku Navodilo za uporabo.
After vaccination, the number of pig herds with signs of infection fell significantly, as did the number of infected pigs within the herds.
Po cepljenju je število čred prašičev z znaki okužbe, pa tudi število okuženih prašičev v čredah, znatno upadlo.
In up to a half of pigs being vaccinated, a slight temporary reaction can occur at the site of injection.
Pri največ polovici cepljenih prašičev se lahko na mestu injiciranja pojavi blaga prehodna reakcija.
The herds of pigs were monitored for signs of infection with the type of Aujeszky's disease virus that is can be caught in the field.
V čredah prašičev so spremljali znake okužbe s vrsto virusa Aujeszkyjeve bolezni, s katerim se je mogoče okužiti v okolju.
An increase in body temperature up to about 40.5°C can occur in a small number of pigs, lasting for up to two days.
Pri manjšem številu prašičev lahko telesna temperatura naraste do približno 40,5°C.
In the future, the immune system will be able to produce antibodies more quickly when it is again exposed to the viruses.
Ko bo imunski sistem naslednjič izpostavljen virusom, bo lahko hitreje izdelal protitelesa.
Vaccination of gilts (female pigs that have not yet had piglets) and sows (female pigs that have had piglets before) with Suvaxyn Aujeszky 783 + O/W can also result in immunity in the pig's offspring.
Cepljenje mladic (samic, ki še niso imele pujskov) in svinj (samic, ki so že imele pujske) z zdravilom Suvaxyn Aujeszky 783 + O/W lahko privede tudi do imunosti njihovih potomcev.
The benefit/risk balance may be found in the scientific discussion module of this EPAR.
Razmerje med koristmi in tveganji najdete v modulu 6 tega evropskega javnega poročila o oceni zdravila (EPAR).
This enables the piglets of vaccinated pigs to be protected against the disease.
To omogoča, da so pujski cepljenih samic zaščiteni pred boleznijo.
The effectiveness of Suvaxyn Aujeszky 783 + O/W has been studied in a large number of pigs in several farms in studies lasting around two years.
Učinkovitost zdravila Suvaxyn Aujeszky 783 + O/W so preučevali pri velikem številu prašičev na različnih farmah v okviru raziskav, ki so trajale približno dve leti.
There was no change in the infection rates in the pigs that were not vaccinated.
Pri necepljenih prašičih sprememb v stopnjah okužbe ni bilo.
Suvaxyn Aujeszky 783 + O/W is given as two 2 ml injections into the muscle of the neck behind the ear, three to four weeks apart.
Zdravilo Suvaxyn Aujeszky 783 + O/W se daje v obliki dveh 2 ml injekcij v mišico vratu za ušesom v razmiku treh do štirih tednov.
Suvaxyn Aujeszky 783 + O/W was effective at preventing infection with the virus.
Zdravilo Suvaxyn Aujeszky 783 + O/W je bilo učinkovito pri preprečevanju okužbe z virusom.
Suvaxyn Aujeszky 783 + O/W is a powder and solvent that are made up into an emulsion (a mixture of oil- and water-based liquids) for injection.
Zdravilo Suvaxyn Aujeszky 783 + O/W je prašek in topilo za pripravo emulzije (zmes tekočin na osnovi olja in vode) za injiciranje.
Suvaxyn Aujeszky 783 + O/W is used to vaccinate pigs from the age of 10 weeks against Aujeszky's disease, an illness similar to rabies that is caused by a herpesvirus.
Zdravilo Suvaxyn Aujeszky 783 + O/W se uporablja za cepljenje prašičev, starih 10 tednov ali več, proti Aujeszkyjevi bolezni, tj. bolezni, podobni steklini, ki jo povzroča herpesvirus.
The Committee for Medicinal Products for Veterinary Use (CVMP) concluded that the benefits of Suvaxyn Aujeszky 783 + O/W exceed the risks for the treatment of active immunisation of pigs from the age of 10 weeks to prevent the mortality and clinical signs of Aujeszky's Disease and to reduce the excretion of Aujeszky's Disease field virus.
Odbor za zdravila za uporabo v veterinarski medicini (CVMP) je sklenil, da so koristi zdravila Suvaxyn Aujeszky 783 + O/W pri aktivni in pasivni imunizaciji prašičev za preprečevanje ali zmanjševanje pogina in kliničnih znakov Aujeszkyjeve bolezni in za zmanjšanje izločanja divjega virusa Aujeszkyjeve bolezni večje od z njim povezanih tveganj.
Suvaxyn Aujeszky 783 + O/W contains small amounts of a weakened form of the virus that causes Aujeszky's disease.
Zdravilo Suvaxyn Aujeszky 783 + O/W vsebuje majhne količine oslabljene oblike virusa, ki povzroča Aujeszkyjevo bolezen.
The European Commission granted a marketing authorisation valid throughout the European Union, for Suvaxyn Aujeszky 783 + O/W on 7 August 1998.
Evropska komisija je dovoljenje za promet z zdravilom Suvaxyn Aujeszky 783 + O/W, veljavno po vsej Evropski uniji, odobrila dne 7. avgusta 1998.
The withdrawal period is the time allowed after administration of the medicine and before the animal can be slaughtered and the meat used for human consumption or eggs or milk used for human consumption.
Koliko časa je potrebno počakati preden se žival lahko zakolje in meso uporabi za prehrano ljudi (karenca)?
Suvaxyn Aujeszky 783 + O/W is a vaccine that contains a live attenuated (weakened) form of Aujeszky's disease virus strain NIA3-783.
Zdravilo Suvaxyn Aujeszky 783 + O/W je cepivo, ki vsebuje živo, atenuirano (oslabljeno) obliko virusa Aujeszkyjeve bolezni, sev NIA3-783.
Other information about Suvaxyn Aujeszky 783 + O/W:
Druge informacije o zdravilu Suvaxyn Aujeszky 783 + O/W:
Suvaxyn Aujeszky 783 + O/W is a vaccine.
Zdravilo Suvaxyn Aujeszky 783 + O/W je cepivo.
What benefit has Suvaxyn Aujeszky 783 + O/W shown during the studies?
Kakšne koristi je zdravilo Suvaxyn Aujeszky 783 + O/W izkazalo med raziskavami?
What is the risk associated with Suvaxyn Aujeszky 783 + O/W?
Kakšna tveganja so povezana z zdravilom Suvaxyn Aujeszky 783 + O/W?
Why has Suvaxyn Aujeszky 783 + O/W been approved?
Zakaj je bilo zdravilo Suvaxyn Aujeszky 783 + O/W odobreno?
How has Suvaxyn Aujeszky 783 + O/W been studied?
Kako je bilo zdravilo Suvaxyn Aujeszky 783 + O/W raziskano?
What is Suvaxyn Aujeszky 783 + O/W?
Kaj je zdravilo Suvaxyn Aujeszky 783 + O/W?
What is Suvaxyn Aujeszky 783 + O/W used for?
Za kaj se zdravilo Suvaxyn Aujeszky 783 + O/W uporablja?
Pregabalin Sandoz GmbH is available as capsules (25, 50, 75, 100, 150, 200, 225 and 300 mg) and can only be obtained with a prescription.
Zdravilo Pregabalin Sandoz GmbH je na voljo v obliki kapsul (25, 50, 75, 100, 150, 200, 225 in 300 mg) in se izdaja le na recept.
This reduces the activity of some of the nerve cells in the brain and spinal cord, reducing the release of other neurotransmitters that are involved in epilepsy and anxiety.
S tem se zmanjša dejavnost nekaterih živčnih celic v možganih in hrbtenjači, zaradi česar se zmanjša sproščanje drugih živčnih prenašalcev, ki so povezani epilepsijo in tesnobo.
The full EPAR and risk management plan summary for Pregabalin Sandoz GmbH can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Celotno evropsko javno poročilo o oceni zdravila (EPAR) in povzetek načrta obvladovanja tveganj za zdravilo Pregabalin Sandoz GmbH sta na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
This is a summary of the European public assessment report (EPAR) for Pregabalin Sandoz GmbH.
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Pregabalin Sandoz GmbH.
The European Commission granted a marketing authorisation valid throughout the European Union for Pregabalin Sandoz GmbH on 19 June 2015.
Evropska komisija je dovoljenje za promet z zdravilom Pregabalin Sandoz GmbH, veljavno po vsej Evropski uniji, izdala 19. junija 2015.
The Agency's Committee for Medicinal Products for Human Use (CHMP) concluded that, in accordance with EU requirements, Pregabalin Sandoz GmbH has been shown to have comparable quality and to be bioequivalent to Lyrica.
Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da je bilo v skladu z zahtevami EU dokazano, da ima zdravilo Pregabalin Sandoz GmbH primerljivo raven kakovosti kot zdravilo Lyrica ter da mu je biološko enakovredno.
(epileptic fits starting in one specific part of the brain) that cannot be controlled with their current treatment;
• epilepsijo, pri čemer se uporablja kot dodatek k obstoječemu zdravljenju pri bolnikih s parcialnimi napadi (epileptičnimi napadi, ki izvirajo iz določenega dela možganov), ki jih ni mogoče nadzorovati s trenutnim zdravljenjem;
Pregabalin Sandoz GmbH is a medicine used to treat adults with the following conditions:
Pregabalin Sandoz GmbH je zdravilo, ki se uporablja za zdravljenje odraslih z naslednjimi boleznimi:
The Committee recommended that Pregabalin Sandoz GmbH be approved for use in the EU.
Priporočil je, da se zdravilo Pregabalin Sandoz GmbH odobri za uporabo v EU.
The active substance in Pregabalin Sandoz GmbH, pregabalin, is similar in structure to the body's own ‘neurotransmitter' gamma‑amino butyric acid (GABA), but has very different biological effects.
Zdravilna učinkovina v zdravilu Pregabalin Sandoz GmbH, pregabalin, ima podobno strukturo kot telesu lastni „živčni prenašalec“ gama-aminomaslena kislina (GABA), vendar ima bistveno drugačne biološke učinke.
What measures are being taken to ensure the safe and effective use of Pregabalin Sandoz GmbH?
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Pregabalin Sandoz GmbH?
For more information about treatment with Pregabalin Sandoz GmbH, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Za več informacij o zdravljenju z zdravilom Pregabalin Sandoz GmbH preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
Because Pregabalin Sandoz GmbH is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.
Ker je zdravilo Pregabalin Sandoz GmbH generično zdravilo in je biološko enakovredno referenčnemu zdravilu, so koristi in tveganja enaki kot pri referenčnem zdravilu.
This means that Pregabalin Sandoz GmbH is similar to a ‘reference medicine' already authorised in the European Union (EU) called Lyrica.
To pomeni, da je podobno „referenčnemu zdravilu“, ki je že odobreno v Evropski uniji (EU), in sicer zdravilu Lyrica.
Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Pregabalin Sandoz GmbH, including the appropriate precautions to be followed by healthcare professionals and patients.
V skladu s tem načrtom so bile v povzetek glavnih značilnosti zdravila in navodilo za njegovo uporabo vključene informacije o varnosti, vključno s previdnostnimi ukrepi, ki jih morajo upoštevati zdravstveni delavci in bolniki.
Stopping treatment with Pregabalin Sandoz GmbH should also be done gradually, over at least a week.
Največji dovoljeni odmerek je 600 mg na dan. Tudi prenehanje zdravljenja z zdravilom Pregabalin Sandoz GmbH mora potekati postopno, in sicer mora trajati najmanj en teden.
For practical information about using Pregabalin Sandoz GmbH, patients should read the package leaflet or contact their doctor or pharmacist.
Za praktične informacije o uporabi zdravila Pregabalin Sandoz GmbH naj bolniki preberejo navodilo za uporabo ali se posvetujejo z zdravnikom ali farmacevtom.
A risk management plan has been developed to ensure that Pregabalin Sandoz GmbH is used as safely as possible.
Za zagotovitev čim varnejše uporabe zdravila Pregabalin Sandoz GmbH je bil pripravljen načrt obvladovanja tveganj.
Pregabalin Sandoz GmbH is a ‘generic medicine'.
Pregabalin Sandoz GmbH je „generično zdravilo“.
Because Pregabalin Sandoz GmbH is a generic medicine, studies in people have been limited to tests to determine that it is bioequivalent to the reference medicine, Lyrica.
Ker je zdravilo Pregabalin Sandoz GmbH generično zdravilo, so bile študije omejene na preskuse za ugotavljanje, ali je biološko enakovredno referenčnemu zdravilu Lyrica.
What are the benefits and risks of Pregabalin Sandoz GmbH?
Kakšne so koristi in tveganja, povezani z zdravilom Pregabalin Sandoz GmbH?
Other information about Pregabalin Sandoz GmbH
Druge informacije o zdravilu Pregabalin Sandoz GmbH
What is Pregabalin Sandoz GmbH and what is it used for?
Kaj je zdravilo Pregabalin Sandoz GmbH in za kaj se uporablja?
Why is Pregabalin Sandoz GmbH approved?
Zakaj je bilo zdravilo Pregabalin Sandoz GmbH odobreno?
Pregabalin Sandoz GmbH contains the active substance pregabalin.
Zdravilo Pregabalin Sandoz GmbH vsebuje zdravilno učinkovino pregabalin.
How has Pregabalin Sandoz GmbH been studied?
Kako je bilo zdravilo Pregabalin Sandoz GmbH raziskano?
How is Pregabalin Sandoz GmbH used?
Kako se zdravilo Pregabalin Sandoz GmbH uporablja?
How does Pregabalin Sandoz GmbH work?
Kako zdravilo Pregabalin Sandoz GmbH deluje?
• 18 months.
18 mesecev.
Results on these end-points were supportive of the primary end-points results.
Rezultati teh končnih točk so podprli rezultate primarnih končnih točk.
The use of gloves is recommended.
Priporoča se uporaba zaščitnih rokavic.
Your doctor will discuss these with you and will explain the potential risks and benefits of your treatment.
Zdravnik se bo z vami o njih pogovoril in vam pojasnil moţna tveganja in koristi vašega zdravljenja.
From a microbiological point of view, the product should be used immediately.
Iz mikrobiološkega vidika je treba zdravilo porabiti takoj.
73% of the cutaneous reactions were reversible within 21 days.
73 % koţnih reakcij je bilo reverzibilnih v 21 dneh.
The infusion will last approximately one hour during which you will be in the hospital.
Infundiranje bo trajalo pribliţno eno uro in med tem časom boste v bolnišnici.
Other appropriate symptomatic measures should be taken, as needed.
Po potrebi se uporabijo še drugi ustrezni simptomatski ukrepi.
Risk Management Plan (RMP) Not applicable.
Načrt za obvladovanje tveganja (RMP) Navedba smiselno ni potrebna.
Such information will allow her/him to decide whether a dose reduction is needed.
Te informacije bodo zdravniku pomagale pri odločitvi, ali je treba odmerek zmanjšati.
During treatment, you may be given other medicines to maintain the number of your blood cells.
Med zdravljenjem boste morda dobivali zdravila za ohranjanje števila krvnih celic.
747 70 Opava-Komárov Czech Republic
747 70 Opava-Komárov Češka
Please tell your doctor or hospital pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without a prescription.
Obvestite svojega zdravnika ali bolnišničnega farmacevta, če jemljete ali ste pred kratkim jemali katerokoli drugo zdravilo, tudi če ste ga dobili brez recepta.
The following information is intended for healthcare professionals only:
Naslednje informacije so namenjene samo zdravstvenemu osebju.
In case of overdose, the patient should be kept in a specialised unit and vital functions closely monitored.
V primeru prevelikega odmerjanja je treba bolnika pridrţati v specializirani enoti in natančno spremljati njegove vitalne funkcije.
The marketing authorisation holder shall submit periodic safety update reports for this product in accordance with the requirements set out in the list of Union reference dates (EURD list) provided fro under Article 107c(7) of Directive 2001/83/EC and published on the European Medicines web-portal.
Imetnik dovoljenja za promet z zdravilom mora redno posodobljena poročila o varnosti zdravila za to zdravilo predloţiti v skladu z zahtevami, določenimi v seznamu referenčnih datumov Unije (seznamu EURD), opredeljenem v členu 107c(7) Direktive 2001/83/ES in objavljenem na evropskem spletnem portalu o zdravilih.
75 to 60 mg/m².
75 na 60 mg/m 2.
Read all of this leaflet carefully before you start using this medicine because it contains important information for you.
Pred uporabo natančno preberite navodilo, ker vsebuje za vas pomembne informacije!
If the patient continues to experience these reactions at 60 mg/m², the treatment should be discontinued.
Če bolnik tudi pri odmerku 60 mg/m še doţivlja te reakcije, je treba zdravljenje prekiniti.
Older people treated with TCF should be closely monitored.
Starejše osebe, ki dobivajo TCF, je treba natančno nadzirati.
This may be moderate to severe and has been associated with death (see section 4.8).
To je lahko zmerno do hudo in je bilo povezano s smrtjo (glejte poglavje 4.8).
No statistical differences were observed between treatment groups for Global Quality of Life.
Med skupinami zdravljenja niso opazili statističnih razlik po oceni globalnega vprašalnika o kakovosti ţivljenja (»Global Quality of Life«).
Cardiac function should be further monitored during treatment (e.g. every three months) to help identify patients who may develop cardiac dysfunction.
Srčno funkcijo je med zdravljenjem treba nadalje nadzorovati (npr. vsake tri mesece), da bi prepoznali bolnice, pri katerih bi se lahko razvila srčna okvara.
Eruptions generally occurred within one week after the docetaxel infusion.
Izbruhi so se ponavadi pojavili v enem tednu po infuziji docetaksela.
Overall response rate (%):
celotni deleţ odziva (%):
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Kot vsa zdravila, ima lahko tudi to zdravilo neţelene učinke, ki pa se ne pojavijo pri vseh bolnikih.
If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2 to 8°C, unless dilution has taken place in controlled and validated aseptic conditions.
Če se ne porabi takoj, je uporabnik odgovoren za čas in pogoje hranjenja pred uporabo, to pa ne bi smelo trajati dlje kot 24 ur pri 2 do 8°C, razen če se je redčenje opravilo v nadzorovanih in preverjeno aseptičnih pogojih.
Older people
Starejše osebe
Pharmacotherapeutic group: Taxanes, ATC Code: L01CD 02
Farmakoterapevtska skupina: taksani; oznaka ATC: L01CD02.
Median time to progression (weeks)
srednji čas do napredovanja bolezni (tedni)
Your doctor may change the dose and frequency of dosing depending on your blood tests, your general condition and your response to Docetaxel Teva Pharma.
Zdravnik bo morda spremenil odmerek in pogostost odmerjanja glede na izvide vaših preiskav krvi, vaše splošno stanje in vaš odziv na zdravilo Docetaxel Teva Pharma.
Both regimens were administered every 3 weeks.
Oba reţima so aplicirali enkrat na 3 tedne.
For combination with trastuzumab, adverse events (all grades) reported in ≥ 10% are displayed.
Pri kombinaciji s trastuzumabom so predstavljeni neţeleni učinki (vseh stopenj), o katerih so poročali pri ≥ 10 %.
This medicinal product must not be mixed with other medicinal products except those mentioned in Section 6.6.
Zdravilo se ne sme mešati z drugimi zdravili, razen s tistimi, ki so omenjena v poglavju 6.6. 6.3 Rok uporabnosti